Skip to Content

PerkinElmer Inc PKI

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Stewardship

PREMIUM

PerkinElmer Reports Relatively Stable 1Q Results; Maintaining Fair Value Estimate

Julie Utterback, CFA Senior Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat PerkinElmer reported first-quarter results that were relatively stable, as negative impacts related to the pandemic in certain end-markets were partially offset by strong resiliency in business and geographical mix. The firm generated $0.66 earnings per share and $653 million in sales, surpassing Capital IQ’s consensus of $0.52 and $634 million, respectively. Management pulled its guidance for 2020 because of the ongoing COVID-19 crisis, but considering the potential for a rebound in future periods, we do not expect to make material changes to our $83 fair value estimate. 

Read Full Analysis

Company Profile

Business Description

PerkinElmer provides instruments, consumables, and services to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes prenatal screening and infectious-disease testing, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.

Contact
940 Winter Street
Waltham, MA, 02451
T +1 781 663-6900
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 30, 2020
Stock Type Slow Growth
Employees 13,000